Biomarker panel for frailty and future muscle weakness in older adults
In 168 older adults from a Japanese biobank, three markers—SMI, apelin and GDF15—were associated with frailty, especially muscle weakness, and predicted later muscle weakness with a concordance index of 0.70. [1]
Automatic summary · not editorially reviewed
The key findings
The analysis included 168 NCGG Biobank participants: 61 robust, 25 pre-frail and 82 frail. [1]
Cross-validation suggested SMI, apelin and GDF15 as potential biomarkers. [1]
Retrospective and prospective analyses indicated the markers predicted future muscle weakness with a concordance index of 0.70. [1]
The source at a glance
- Study type / format
- Biobank-based biomarker study reported in an abstract
- Population / context
- 168 older adults in the NCGG Biobank (61 robust, 25 pre-frail, 82 frail).
- Summary based on
- Study abstract
- Original publication
- September 17, 2026
Frailty markers studied in 168 biobank participants
The authors describe frailty as a complex geriatric syndrome with age-related declines in physiological function and cognitive reserve. They analyzed 168 people enrolled in the NCGG Biobank: 61 robust, 25 pre-frail and 82 frail. Clinical information, blood-test data, aging-related factors and gene-expression data were combined. The aim was to find minimally invasive, objective biomarkers linked to frailty progression and to the five J-CHS criteria: unintentional weight loss, self-reported exhaustion, muscle weakness, slow walking speed and low physical activity.
Supporting source [1]
Three candidate markers linked to muscle weakness
A first linear regression linked one clinical factor, five aging-related factors and 251 gene-expression factors to frailty. Separate logistic regressions for each J-CHS component highlighted six candidate biomarkers. Cross-validation suggested three of them—SMI, apelin and GDF15—as potential biomarkers. Retrospective and prospective analyses indicated these markers predicted future muscle weakness, with a concordance index of 0.70. The authors conclude the panel is associated with frailty, particularly muscle weakness, a major J-CHS component.
Supporting source [1]
Abstract-only scope and need for larger cohorts
The longitudinal analyses suggested the markers may be associated with future muscle weakness in initially robust older adults. The authors state that validation in larger prospective cohorts is warranted. This explainer is based only on the abstract; the full text was not reviewed. The design, follow-up duration and exact outcome definitions are not reported in the abstract, and the associations do not establish that the markers cause frailty or muscle weakness.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. Design details, follow-up duration and outcome definitions are not reported in the abstract. Associations do not show causation, and validation in larger prospective cohorts is stated as needed.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Yamakawa A, Hosoyama T, Takemura M, Niida S, Ozaki K, Satake S, Shigemizu D. · europepmc.org · September 17, 2026